Skip to content
Back to meeting Original
Urology Times· @UrologyTimes · X·· 2 days agoScore70

LITESPARK-011

Body

WATCH: Daniel Heng, MD, MPH, FRCPC, (@DrDanielHeng) highlights final results from LITESPARK-011, which evaluated belzutifan plus lenvatinib vs cabozantinib in patients with advanced ccRCC following anti-PD-(L)1 therapy. #ESMO26 https://www.urologytimes.com/view/daniel-heng-md-highlights-final-litespark-011-results-in-advanced-ccrcc

43 views · 0 likes · 0 reposts · 0 replies

Conference abstracts

Source: Urology Times · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.